$RGLS
Regulus Therapeutics Inc. Stock $rgls

$rgls Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-K Financial Statement

#000162828021004294 Filed on March 09, 2021

Income Statement

Concept	2020 Q4	2019 Q4	2019 Q3
Revenue	$5.000M	$18.00K	$18.00K
YoY Change	27677.78%	0.0%	0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.080M	$2.360M	$2.570M
YoY Change	-11.86%	-14.18%	-14.05%
% of Gross Profit
Research & Development	$3.850M	$1.970M	$2.440M
YoY Change	95.43%	-62.55%	-64.53%
% of Gross Profit
Depreciation & Amortization	$110.0K	$130.0K	$130.0K
YoY Change	-15.38%	-77.97%	-76.36%
% of Gross Profit
Operating Expenses	$6.028M	$4.453M	$5.011M
YoY Change	35.37%	-44.34%	-49.24%
Operating Profit			-$4.993M
YoY Change			-49.33%
Interest Expense	-$290.0K	-$460.0K	$517.0K
YoY Change	-36.96%	-11.54%	-16.61%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$1.320M	-$4.890M	-$5.423M
YoY Change	-73.01%	-42.47%	-47.21%
Income Tax	$10.00K	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.322M	-$4.893M	-$5.423M
YoY Change	-72.98%	-42.86%	-47.21%
Net Earnings / Revenue	-26.44%	-27183.33%	-30127.78%
Basic Earnings Per Share
Diluted Earnings Per Share	-$27.60K	-$233.0K	-$260.0K
COMMON SHARES
Basic Shares Outstanding	39.16M shares	20.93M shares	20.82M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2019 Q4	2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.10M	$34.10M	$14.60M
YoY Change	-8.8%	145.32%	-28.78%
Cash & Equivalents	$31.09M	$34.12M	$14.65M
Short-Term Investments
Other Short-Term Assets	$1.826M	$1.221M	$358.0K
YoY Change	49.55%	7.11%	-50.07%
Inventory
Prepaid Expenses	$3.314M	$3.924M	$3.826M
Receivables	$500.0K	$1.100M	$700.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$36.73M	$40.41M	$19.53M
YoY Change	-9.1%	109.42%	-23.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$472.0K	$921.0K	$1.042M
YoY Change	-48.75%	-88.2%	-87.48%
Goodwill
YoY Change
Intangibles	$125.0K	$266.0K	$303.0K
YoY Change	-53.01%	-46.8%	-55.18%
Long-Term Investments
YoY Change
Other Assets	$24.00K	$487.0K	$536.0K
YoY Change	-95.07%	49.39%	63.91%
Total Long-Term Assets	$874.0K	$1.674M	$1.881M
YoY Change	-47.79%	-80.61%	-79.83%
TOTAL ASSETS
Total Short-Term Assets	$36.73M	$40.41M	$19.53M
Total Long-Term Assets	$874.0K	$1.674M	$1.881M
Total Assets	$37.60M	$42.08M	$21.41M
YoY Change	-10.64%	50.68%	-38.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$535.0K	$1.321M	$1.521M
YoY Change	-59.5%	-22.93%	23.16%
Accrued Expenses	$581.0K	$770.0K	$1.212M
YoY Change	-24.55%	-52.62%	-34.7%
Deferred Revenue	$0.00	$6.000K	$24.00K
YoY Change	-100.0%	-99.77%	-66.67%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$4.700M	$14.90M	$14.90M
YoY Change	-68.46%	-10.24%	-21.99%
Total Short-Term Liabilities	$11.58M	$21.60M	$21.00M
YoY Change	-46.39%	-18.94%	-18.13%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$100.0K	$100.0K
YoY Change	-100.0%
Other Long-Term Liabilities	$0.00	$468.0K	$549.0K
YoY Change	-100.0%	51.46%	47.18%
Total Long-Term Liabilities	$0.00	$468.0K	$549.0K
YoY Change	-100.0%	51.46%	47.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.58M	$21.60M	$21.00M
Total Long-Term Liabilities	$0.00	$468.0K	$549.0K
Total Liabilities	$11.58M	$22.07M	$21.55M
YoY Change	-47.53%	-34.68%	-35.06%
SHAREHOLDERS EQUITY
Retained Earnings	-$427.0M	-$411.3M	-$406.4M
YoY Change	3.82%	4.73%	5.79%
Common Stock	$453.1M	$431.3M	$406.3M
YoY Change	5.04%	11.49%	5.31%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$26.03M	$20.02M	-$143.0K
YoY Change
Total Liabilities & Shareholders Equity	$37.60M	$42.08M	$21.41M
YoY Change	-10.64%	50.68%	-38.42%

Cashflow Statement

Concept	2020 Q4	2019 Q4	2019 Q3
OPERATING ACTIVITIES
Net Income	-$1.322M	-$4.893M	-$5.423M
YoY Change	-72.98%	-42.86%	-47.21%
Depreciation, Depletion And Amortization	$110.0K	$130.0K	$130.0K
YoY Change	-15.38%	-77.97%	-76.36%
Cash From Operating Activities	$3.190M	-$4.980M	-$4.720M
YoY Change	-164.06%	24.19%	-58.78%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$60.00K	-$160.0K
YoY Change	-100.0%		700.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$30.00K
YoY Change		-100.0%	-99.77%
Cash From Investing Activities	$0.00	-$60.00K	-$140.0K
YoY Change	-100.0%	-100.93%	-101.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.05M	24.51M	-70.00K
YoY Change	-59.0%	-1053.7%	-92.13%
NET CHANGE
Cash From Operating Activities	3.190M	-4.980M	-4.720M
Cash From Investing Activities	0.000	-60.00K	-140.0K
Cash From Financing Activities	10.05M	24.51M	-70.00K
Net Change In Cash	13.24M	19.47M	-4.930M
YoY Change	-32.0%	-14007.14%	-935.59%
FREE CASH FLOW
Cash From Operating Activities	$3.190M	-$4.980M	-$4.720M
Capital Expenditures	$0.00	-$60.00K	-$160.0K
Free Cash Flow	$3.190M	-$4.920M	-$4.560M
YoY Change	-164.84%	22.69%	-60.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Registrant Name EntityRegistrantName	REGULUS THERAPEUTICS INC.
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0001505512
CY2019Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2020Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesCurrent
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:OtherAssetsNoncurrent
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList	us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	us-gaap:OtherLiabilitiesNoncurrent
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	001-35670
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-4738379
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	10628 Science Center Drive, Suite 225
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
CY2020	dei	City Area Code CityAreaCode	858
CY2020	dei	Local Phone Number LocalPhoneNumber	202-6300
CY2020	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2020	dei	Trading Symbol TradingSymbol	RGLS
CY2020	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q2	dei	Entity Public Float EntityPublicFloat	22500000	USD
CY2020	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	true
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	72504772	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31087000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34121000	USD
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	503000	USD
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	1141000	USD
CY2020Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3314000	USD
CY2019Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3924000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1826000	USD
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1221000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	36730000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	40407000	USD
CY2020Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	472000	USD
CY2019Q4	us-gaap	Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization	921000	USD
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	125000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	266000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	277000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	487000	USD
CY2020Q4	us-gaap	Assets Assets	37604000	USD
CY2019Q4	us-gaap	Assets Assets	42081000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	535000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1321000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	581000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	770000	USD
CY2020Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	1097000	USD
CY2019Q4	rgls	Accrued Research And Development Current AccruedResearchAndDevelopmentCurrent	147000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1743000	USD
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1676000	USD
CY2020Q4	us-gaap	Debt Current DebtCurrent	4652000	USD
CY2019Q4	us-gaap	Debt Current DebtCurrent	14631000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	0	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	6000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2970000	USD
CY2019Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3047000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11578000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	21598000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	468000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	11578000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	22066000	USD
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67432712	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	67432712	shares
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	21018663	shares
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	21018663	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	67000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	21000	USD
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	453002000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	431305000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-427045000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-411315000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20015000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37604000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42081000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10006000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6832000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15347000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12349000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8814000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11317000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	24161000	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	23666000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-14155000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-16834000	USD
CY2020	us-gaap	Interest And Other Income InterestAndOtherIncome	233000	USD
CY2019	us-gaap	Interest And Other Income InterestAndOtherIncome	374000	USD
CY2020	us-gaap	Interest Expense InterestExpense	1808000	USD
CY2019	us-gaap	Interest Expense InterestExpense	2131000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15730000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-18591000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15730000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18592000	USD
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.45
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.08
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34977378	shares
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	17260176	shares
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-5854000	USD
CY2019	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	USD
CY2019	rgls	Stock Issued During Period Shares Preferred Stock Warrants From Private Placement Netof Offering Costs Value StockIssuedDuringPeriodSharesPreferredStockWarrantsFromPrivatePlacementNetofOfferingCostsValue	40084000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2288000	USD
CY2019	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	3000	USD
CY2019	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2083000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18592000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	20015000	USD
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5000	USD
CY2020	rgls	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	692000	USD
CY2020	rgls	Stock Issued During Period Shares Preferred Stock Warrants From Private Placement Netof Offering Costs Value StockIssuedDuringPeriodSharesPreferredStockWarrantsFromPrivatePlacementNetofOfferingCostsValue	18166000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2614000	USD
CY2020	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	2000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	262000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15730000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	26026000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15730000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-18592000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	467000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	931000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	2614000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	2288000	USD
CY2020	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	0	USD
CY2019	rgls	Gainon Reductionof Lease Liability GainonReductionofLeaseLiability	1839000	USD
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	154000	USD
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	293000	USD
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-638000	USD
CY2019	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	1115000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-610000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-270000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	395000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	242000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-786000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-393000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-188000	USD
CY2019	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-281000	USD
CY2020	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	949000	USD
CY2019	rgls	Increase Decrease In Accrued Research And Development Expenses IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses	-427000	USD
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	66000	USD
CY2019	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	75000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-6000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-2572000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-929000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-1895000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12536000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19821000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	221000	USD
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	318000	USD
CY2020	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	11000	USD
CY2019	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	23000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	74000	USD
CY2020	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	18166000	USD
CY2019	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	40084000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	957000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2086000	USD
CY2020	rgls	Proceeds From Federal Program ProceedsFromFederalProgram	662000	USD
CY2019	rgls	Proceeds From Federal Program ProceedsFromFederalProgram	0	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5000	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	USD
CY2020	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	277000	USD
CY2019	rgls	Paymentson Finance Leases PaymentsonFinanceLeases	263000	USD
CY2020	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	10000000	USD
CY2019	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1977000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	9513000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	39933000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3034000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20186000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34121000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	13935000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	31087000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34121000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1356000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1655000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
CY2020	rgls	Noncash Unsettled Sales Of Common Stock Through Atm NoncashUnsettledSalesOfCommonStockThroughATM	392000	USD
CY2019	rgls	Noncash Unsettled Sales Of Common Stock Through Atm NoncashUnsettledSalesOfCommonStockThroughATM	0	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	3000	USD
CY2020	rgls	Financingfrom Sale Proceeds Debt Agreement Revenues FinancingfromSaleProceedsDebtAgreementRevenues	483400000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31100000	USD
CY2020	us-gaap	Use Of Estimates UseOfEstimates	Use of EstimatesOur financial statements are prepared in accordance with GAAP, which requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our financial statements and accompanying notes. An estimated loss contingency is accrued in our financial statements if it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. Although these estimates are based on our knowledge of current events and actions we may undertake in the future, actual results may ultimately differ from these estimates and assumptions. Though the impact of the COVID-19 pandemic to our business and operating results presents additional uncertainty, we continue to use the best information available to inform our critical accounting estimates.
CY2020	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:15pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Credit Risk </span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash equivalents. We maintain deposits in federally insured financial institutions in excess of federally insured limits. We have not experienced any material losses in such accounts and believe we are not exposed to significant risk. We maintain our cash equivalents with two highly accredited financial institutions. We have historically invested our excess cash primarily in certificates of deposit and debt instruments of financial institutions and corporations, United States Treasury securities and United States government-sponsored enterprise securities. Additionally, we adhere to established guidelines regarding approved investments and maturities of investments, which are designed to preserve their principal value and maintain liquidity.</span></div>
CY2020	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23741466	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6569337	shares
CY2019	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	0	USD
CY2020Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	26901000	USD
CY2019Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	8909000	USD
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	5000000.0	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5331000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4859000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	5331000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4410000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	921000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	500000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	900000	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	100000	USD
CY2020Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	100000	USD
CY2020	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P13Y10M24D
CY2018Q4	rgls	Upfront Payment Received UpfrontPaymentReceived	2500000	USD
CY2019Q1	rgls	Upfront Payment Received UpfrontPaymentReceived	1800000	USD
CY2020Q2	rgls	Forgiveness Amount Threshold ForgivenessAmountThreshold	500000	USD
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	67432712	shares
CY2020Q4	rgls	Common Stock Voting Rights Votes CommonStockVotingRightsVotes	1	vote
CY2020Q4	rgls	Sale Of Stock Value Of Shares Available SaleOfStockValueOfSharesAvailable	7100000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6813000	shares
CY2020Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	93260000	shares
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2614000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2288000	USD
CY2020	rgls	Defined Contribution Minimum Age Requirement Of Eligible Employees DefinedContributionMinimumAgeRequirementOfEligibleEmployees	P18Y
CY2020	rgls	Defined Contribution Plan Employee Contributions Percentageof Eligible Compensation DefinedContributionPlanEmployeeContributionsPercentageofEligibleCompensation	0.50
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.50
CY2020	us-gaap	Defined Contribution Plan Maximum Annual Contributions Per Employee Percent DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent	0.06
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	100000	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-13000	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-13000	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12000	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-12000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	12000	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	13000	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	12000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	13000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3309000	USD
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3904000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-927000	USD
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1390000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1216000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	374000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	2606000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	603000	USD
CY2020	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-14000	USD
CY2019	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-358000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1644000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	3934000	USD
CY2020	rgls	Effective Income Tax Rate Reconciliation Reservefor Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationReserveforUncertainTaxPositionsAmount	1179000	USD
CY2019	rgls	Effective Income Tax Rate Reconciliation Reservefor Uncertain Tax Positions Amount EffectiveIncomeTaxRateReconciliationReserveforUncertainTaxPositionsAmount	1444000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	37000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	46000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	82747000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	79675000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	34337000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	33429000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	1000	USD
CY2020Q4	rgls	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	715000	USD
CY2019Q4	rgls	Deferred Tax Assets Property Plant And Equipment And Intangible Assets DeferredTaxAssetsPropertyPlantAndEquipmentAndIntangibleAssets	782000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	283000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1389000	USD
CY2020Q4	rgls	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	88000	USD
CY2019Q4	rgls	Deferred Tax Assets Lease Liabilities DeferredTaxAssetsLeaseLiabilities	164000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	281000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	461000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	118451000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	115901000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	282000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	325000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	118169000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	115576000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118169000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	115564000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	USD
CY2019Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	12000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	118200000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16573000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	14700000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	7000	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1367000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	1880000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17939000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	16573000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	17900000	USD
CY2020Q4	rgls	Lease Right Of Use Asset LeaseRightOfUseAsset	541000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	14500000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2015Q3	us-gaap	Net Rentable Area NetRentableArea	59248	sqft
CY2015Q3	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P96M
CY2015Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	1400000	USD
CY2017Q4	rgls	Tenant Improvement Allowance TenantImprovementAllowance	8200000	USD
CY2019Q1	rgls	Lease Expense Extinguished LeaseExpenseExtinguished	14400000	USD
CY2020	rgls	Noncash Leasehold Improvements NoncashLeaseholdImprovements	5600000	USD
CY2020	rgls	Noncash Gain Dueto Reductionof Lease Liability NoncashGainDuetoReductionofLeaseLiability	1300000	USD
CY2020Q4	us-gaap	Deferred Costs Leasing Accumulated Amortization DeferredCostsLeasingAccumulatedAmortization	900000	USD
CY2020	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	-1600000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	253000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	464000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	288000	USD
CY2019Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	466000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	361000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	56000	USD
CY2019Q4	rgls	Lease Right Of Use Asset LeaseRightOfUseAsset	930000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	417000	USD
CY2019Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	277000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	417000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2019Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	56000	USD
CY2020Q4	rgls	Lease Liabilities LeaseLiabilities	473000	USD
CY2019Q4	rgls	Lease Liabilities LeaseLiabilities	1111000	USD
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	278000	USD
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	715000	USD
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	178000	USD
CY2019	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	182000	USD
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	10000	USD
CY2019	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	5000	USD
CY2020	us-gaap	Lease Cost LeaseCost	188000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-1524000	USD
CY2020	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	10000	USD
CY2019	us-gaap	Lease Cost LeaseCost	187000	USD
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	429000	USD
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	756000	USD
CY2019	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	24000	USD
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	277000	USD
CY2019	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	263000	USD
CY2020	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	716000	USD
CY2019	rgls	Operatingand Finance Lease Payments OperatingandFinanceLeasePayments	1043000	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	778000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P2Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y2M12D
CY2019Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M12D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.109
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049
CY2019Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.049
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	442000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	56000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	442000	USD
CY2020Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	56000	USD
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	25000	USD
CY2020Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	0	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	417000	USD
CY2020Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	56000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	417000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	56000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5000000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	5541000	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	6496000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	6095000	USD
CY2020Q4	us-gaap	Operating Expenses OperatingExpenses	6028000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-5937000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-6947000	USD
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-1322000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.25
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2020Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6778000	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
CY2019Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	18000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	9516000	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	4686000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	5011000	USD
CY2019Q4	us-gaap	Operating Expenses OperatingExpenses	4453000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-3260000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-5016000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	-5423000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-4893000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.31
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.30
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2019Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23

Files In Submission

Name	View Source	Status
0001628280-21-004294-index-headers.html	Edgar Link	pending
0001628280-21-004294-index.html	Edgar Link	pending
0001628280-21-004294.txt	Edgar Link	pending
0001628280-21-004294-xbrl.zip	Edgar Link	pending
a2020ex-231xconsentofindep.htm	Edgar Link	pending
a2020ex-311xcertofprincipa.htm	Edgar Link	pending
a2020ex-312xcertofprincipa.htm	Edgar Link	pending
a2020ex-321xcertpursuantto.htm	Edgar Link	pending
exh1013-josephphagansalary.htm	Edgar Link	pending
exh1014-josephphagansalary.htm	Edgar Link	pending
exh1018-drygindenisemplo.htm	Edgar Link	pending
exh1018-drygindenisemplo001.jpg	Edgar Link	pending
exh1018-drygindenisemplo002.jpg	Edgar Link	pending
exh1018-drygindenisemplo003.jpg	Edgar Link	pending
exh1018-drygindenisemplo004.jpg	Edgar Link	pending
exh1018-drygindenisemplo005.jpg	Edgar Link	pending
exh1018-drygindenisemplo006.jpg	Edgar Link	pending
exh1018-drygindenisemplo007.jpg	Edgar Link	pending
exh1018-drygindenisemplo008.jpg	Edgar Link	pending
exh1018-drygindenisemplo009.jpg	Edgar Link	pending
exh1018-drygindenisemplo010.jpg	Edgar Link	pending
exh1018-drygindenisemplo011.jpg	Edgar Link	pending
exh1018-drygindenisemplo012.jpg	Edgar Link	pending
exh1018-drygindenisemplo013.jpg	Edgar Link	pending
exh1018-drygindenisemplo014.jpg	Edgar Link	pending
exh1018-drygindenisemplo015.jpg	Edgar Link	pending
exh1018-drygindenisemplo016.jpg	Edgar Link	pending
exh1030-regulusxex1032to10.htm	Edgar Link	pending
exh1044-leaseagreement.htm	Edgar Link	pending
exh1045-assignmentandass.htm	Edgar Link	pending
exh1045-assignmentandass001.jpg	Edgar Link	pending
exh1045-assignmentandass002.jpg	Edgar Link	pending
exh1045-assignmentandass003.jpg	Edgar Link	pending
exh1045-assignmentandass004.jpg	Edgar Link	pending
exh1045-assignmentandass005.jpg	Edgar Link	pending
exh1045-assignmentandass006.jpg	Edgar Link	pending
exh1045-assignmentandass007.jpg	Edgar Link	pending
exh1045-assignmentandass008.jpg	Edgar Link	pending
exh1045-assignmentandass009.jpg	Edgar Link	pending
exh1045-assignmentandass010.jpg	Edgar Link	pending
exh1045-assignmentandass011.jpg	Edgar Link	pending
exh1045-assignmentandass012.jpg	Edgar Link	pending
exh1045-assignmentandass013.jpg	Edgar Link	pending
exh1045-assignmentandass014.jpg	Edgar Link	pending
exh1045-assignmentandass015.jpg	Edgar Link	pending
exh1045-assignmentandass016.jpg	Edgar Link	pending
exh1045-assignmentandass017.jpg	Edgar Link	pending
exh1045-assignmentandass018.jpg	Edgar Link	pending
exh1045-assignmentandass019.jpg	Edgar Link	pending
exh1045-assignmentandass020.jpg	Edgar Link	pending
exh1045-assignmentandass021.jpg	Edgar Link	pending
exh1045-assignmentandass022.jpg	Edgar Link	pending
exh1045-assignmentandass023.jpg	Edgar Link	pending
exh1045-assignmentandass024.jpg	Edgar Link	pending
exh1045-assignmentandass025.jpg	Edgar Link	pending
exh1045-assignmentandass026.jpg	Edgar Link	pending
exh1045-assignmentandass027.jpg	Edgar Link	pending
exh1045-assignmentandass028.jpg	Edgar Link	pending
exh1045-assignmentandass029.jpg	Edgar Link	pending
exh1045-assignmentandass030.jpg	Edgar Link	pending
exh1045-assignmentandass031.jpg	Edgar Link	pending
exh1045-assignmentandass032.jpg	Edgar Link	pending
exh1045-assignmentandass033.jpg	Edgar Link	pending
exh1045-assignmentandass034.jpg	Edgar Link	pending
exh1045-assignmentandass035.jpg	Edgar Link	pending
exh1045-assignmentandass036.jpg	Edgar Link	pending
exh1045-assignmentandass037.jpg	Edgar Link	pending
exh1045-assignmentandass038.jpg	Edgar Link	pending
exh1045-assignmentandass039.jpg	Edgar Link	pending
exh1045-assignmentandass040.jpg	Edgar Link	pending
exh1045-assignmentandass041.jpg	Edgar Link	pending
exh1045-assignmentandass042.jpg	Edgar Link	pending
exh1045-assignmentandass043.jpg	Edgar Link	pending
exh1045-assignmentandass044.jpg	Edgar Link	pending
exh1045-assignmentandass045.jpg	Edgar Link	pending
exh1045-assignmentandass046.jpg	Edgar Link	pending
exh1045-assignmentandass047.jpg	Edgar Link	pending
exh1045-assignmentandass048.jpg	Edgar Link	pending
exh1045-assignmentandass049.jpg	Edgar Link	pending
exh1045-assignmentandass050.jpg	Edgar Link	pending
exh1045-assignmentandass051.jpg	Edgar Link	pending
exh1045-assignmentandass052.jpg	Edgar Link	pending
exh1045-assignmentandass053.jpg	Edgar Link	pending
exh1045-assignmentandass054.jpg	Edgar Link	pending
exh1045-assignmentandass055.jpg	Edgar Link	pending
exh1045-assignmentandass056.jpg	Edgar Link	pending
exh1045-assignmentandass057.jpg	Edgar Link	pending
exh1045-assignmentandass058.jpg	Edgar Link	pending
exh1045-assignmentandass059.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_101.jpg	Edgar Link	pending
image_11.jpg	Edgar Link	pending
image_21.jpg	Edgar Link	pending
image_31.jpg	Edgar Link	pending
image_41.jpg	Edgar Link	pending
image_51.jpg	Edgar Link	pending
image_61.jpg	Edgar Link	pending
image_71.jpg	Edgar Link	pending
image_81.jpg	Edgar Link	pending
image_91.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rgls-20201231.htm	Edgar Link	pending
rgls-20201231.xsd	Edgar Link	pending
rgls-20201231_cal.xml	Edgar Link	unprocessable
rgls-20201231_def.xml	Edgar Link	unprocessable
rgls-20201231_g1.jpg	Edgar Link	pending
rgls-20201231_htm.xml	Edgar Link	completed
rgls-20201231_lab.xml	Edgar Link	unprocessable
rgls-20201231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RGLS
Regulus Therapeutics Inc. Stock $rgls

2020 Q4 Form 10-K Financial Statement

#000162828021004294 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS Regulus Therapeutics Inc. Stock $rgls

2020 Q4 Form 10-K Financial Statement

#000162828021004294 Filed on March 09, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RGLS
Regulus Therapeutics Inc. Stock $rgls